Loading…

Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis

Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatry research 2011-05, Vol.187 (1), p.42-48
Main Authors: Stauffer, Virginia L, Case, Michael, Kinon, Bruce J, Conley, Robert, Ascher-Svanum, Haya, Kollack-Walker, Sara, Kane, John, McEvoy, Joseph, Lieberman, Jeffrey
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703
cites cdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703
container_end_page 48
container_issue 1
container_start_page 42
container_title Psychiatry research
container_volume 187
creator Stauffer, Virginia L
Case, Michael
Kinon, Bruce J
Conley, Robert
Ascher-Svanum, Haya
Kollack-Walker, Sara
Kane, John
McEvoy, Joseph
Lieberman, Jeffrey
description Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.
doi_str_mv 10.1016/j.psychres.2010.11.017
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_860188813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165178110007092</els_id><sourcerecordid>860188813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEokvhFSpfEKcsHiexnQsCVeWPVIkDcLa8zkTrbTYOHm9RHoJ3xunuUokLJ1v2b76xv2-K4gr4GjjIt7v1RLPbRqS14MshrDmoJ8UKtBKlAlE9LVYZbEpQGi6KF0Q7zrmAtn1eXAgAqVvBV8XvGxuHmWWdKYyELAVmx-QfxEPyjqUtRjvNzBKzzA1-9M4ObG_jHUYWekaHDeHPA47pUcSPSxlLEW3aLzeZm2zyeUvsl09b1vtIqcTJU-iQHbuRp5fFs94OhK9O62Xx4-PN9-vP5e3XT1-uP9yWrm5EKl0rne21dNK2kotKSnC1VbaqhWvaqpWN1thXVaMs1NyKrulVJzsnhdw0SvHqsnhz1J1iyG-nZPaeHA6DHTEcyGjJQWsNVSblkXQxEEXszRR9_v1sgJslCbMz5yTMkoQBMDmJXHh1anHY7LH7W3a2PgOvT4ClbGkf7eg8PXI1b5v6Qej9kcNsyL3HaMhlJx12PqJLpgv-_29594_EOcg7nJF24RDHbLcBQ8Jw822Zm2VsIE-M4q2o_gCpscJs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860188813</pqid></control><display><type>article</type><title>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</title><source>Elsevier</source><creator>Stauffer, Virginia L ; Case, Michael ; Kinon, Bruce J ; Conley, Robert ; Ascher-Svanum, Haya ; Kollack-Walker, Sara ; Kane, John ; McEvoy, Joseph ; Lieberman, Jeffrey</creator><creatorcontrib>Stauffer, Virginia L ; Case, Michael ; Kinon, Bruce J ; Conley, Robert ; Ascher-Svanum, Haya ; Kollack-Walker, Sara ; Kane, John ; McEvoy, Joseph ; Lieberman, Jeffrey</creatorcontrib><description>Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.</description><identifier>ISSN: 0165-1781</identifier><identifier>EISSN: 1872-7123</identifier><identifier>DOI: 10.1016/j.psychres.2010.11.017</identifier><identifier>PMID: 21168920</identifier><identifier>CODEN: PSRSDR</identifier><language>eng</language><publisher>Kidlington: Elsevier Ireland Ltd</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - therapeutic use ; Basal Ganglia Diseases - chemically induced ; Benzodiazepines - therapeutic use ; Biological and medical sciences ; Double-Blind Method ; Female ; Follow-Up Studies ; Haloperidol ; Haloperidol - therapeutic use ; Humans ; International Cooperation ; Male ; Medical sciences ; Mental Disorders - drug therapy ; Mental Disorders - physiopathology ; Neuropharmacology ; Olanzapine ; Pharmacology. Drug treatments ; Prediction models ; Predictive Value of Tests ; Psychiatric Status Rating Scales ; Psychiatry ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Schizophrenia ; Time Factors ; Treatment Outcome ; Weight Gain - drug effects ; Young Adult</subject><ispartof>Psychiatry research, 2011-05, Vol.187 (1), p.42-48</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</citedby><cites>FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24095417$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21168920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stauffer, Virginia L</creatorcontrib><creatorcontrib>Case, Michael</creatorcontrib><creatorcontrib>Kinon, Bruce J</creatorcontrib><creatorcontrib>Conley, Robert</creatorcontrib><creatorcontrib>Ascher-Svanum, Haya</creatorcontrib><creatorcontrib>Kollack-Walker, Sara</creatorcontrib><creatorcontrib>Kane, John</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Lieberman, Jeffrey</creatorcontrib><title>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</title><title>Psychiatry research</title><addtitle>Psychiatry Res</addtitle><description>Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Basal Ganglia Diseases - chemically induced</subject><subject>Benzodiazepines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Haloperidol</subject><subject>Haloperidol - therapeutic use</subject><subject>Humans</subject><subject>International Cooperation</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental Disorders - drug therapy</subject><subject>Mental Disorders - physiopathology</subject><subject>Neuropharmacology</subject><subject>Olanzapine</subject><subject>Pharmacology. Drug treatments</subject><subject>Prediction models</subject><subject>Predictive Value of Tests</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychiatry</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Schizophrenia</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Weight Gain - drug effects</subject><subject>Young Adult</subject><issn>0165-1781</issn><issn>1872-7123</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQxiMEokvhFSpfEKcsHiexnQsCVeWPVIkDcLa8zkTrbTYOHm9RHoJ3xunuUokLJ1v2b76xv2-K4gr4GjjIt7v1RLPbRqS14MshrDmoJ8UKtBKlAlE9LVYZbEpQGi6KF0Q7zrmAtn1eXAgAqVvBV8XvGxuHmWWdKYyELAVmx-QfxEPyjqUtRjvNzBKzzA1-9M4ObG_jHUYWekaHDeHPA47pUcSPSxlLEW3aLzeZm2zyeUvsl09b1vtIqcTJU-iQHbuRp5fFs94OhK9O62Xx4-PN9-vP5e3XT1-uP9yWrm5EKl0rne21dNK2kotKSnC1VbaqhWvaqpWN1thXVaMs1NyKrulVJzsnhdw0SvHqsnhz1J1iyG-nZPaeHA6DHTEcyGjJQWsNVSblkXQxEEXszRR9_v1sgJslCbMz5yTMkoQBMDmJXHh1anHY7LH7W3a2PgOvT4ClbGkf7eg8PXI1b5v6Qej9kcNsyL3HaMhlJx12PqJLpgv-_29594_EOcg7nJF24RDHbLcBQ8Jw822Zm2VsIE-M4q2o_gCpscJs</recordid><startdate>20110515</startdate><enddate>20110515</enddate><creator>Stauffer, Virginia L</creator><creator>Case, Michael</creator><creator>Kinon, Bruce J</creator><creator>Conley, Robert</creator><creator>Ascher-Svanum, Haya</creator><creator>Kollack-Walker, Sara</creator><creator>Kane, John</creator><creator>McEvoy, Joseph</creator><creator>Lieberman, Jeffrey</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110515</creationdate><title>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</title><author>Stauffer, Virginia L ; Case, Michael ; Kinon, Bruce J ; Conley, Robert ; Ascher-Svanum, Haya ; Kollack-Walker, Sara ; Kane, John ; McEvoy, Joseph ; Lieberman, Jeffrey</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Basal Ganglia Diseases - chemically induced</topic><topic>Benzodiazepines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Haloperidol</topic><topic>Haloperidol - therapeutic use</topic><topic>Humans</topic><topic>International Cooperation</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental Disorders - drug therapy</topic><topic>Mental Disorders - physiopathology</topic><topic>Neuropharmacology</topic><topic>Olanzapine</topic><topic>Pharmacology. Drug treatments</topic><topic>Prediction models</topic><topic>Predictive Value of Tests</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychiatry</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Schizophrenia</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Weight Gain - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stauffer, Virginia L</creatorcontrib><creatorcontrib>Case, Michael</creatorcontrib><creatorcontrib>Kinon, Bruce J</creatorcontrib><creatorcontrib>Conley, Robert</creatorcontrib><creatorcontrib>Ascher-Svanum, Haya</creatorcontrib><creatorcontrib>Kollack-Walker, Sara</creatorcontrib><creatorcontrib>Kane, John</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Lieberman, Jeffrey</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stauffer, Virginia L</au><au>Case, Michael</au><au>Kinon, Bruce J</au><au>Conley, Robert</au><au>Ascher-Svanum, Haya</au><au>Kollack-Walker, Sara</au><au>Kane, John</au><au>McEvoy, Joseph</au><au>Lieberman, Jeffrey</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</atitle><jtitle>Psychiatry research</jtitle><addtitle>Psychiatry Res</addtitle><date>2011-05-15</date><risdate>2011</risdate><volume>187</volume><issue>1</issue><spage>42</spage><epage>48</epage><pages>42-48</pages><issn>0165-1781</issn><eissn>1872-7123</eissn><coden>PSRSDR</coden><abstract>Abstract Early response to antipsychotic medication has been shown to accurately predict later response to continued use of the same treatment in patients with chronic schizophrenia. This study examines whether this predictive pattern exists for patients with first-episode psychosis. We used a data-driven threshold for early response of ≥ 26.2% improvement from baseline on the Positive and Negative Syndrome Scale (PANSS0–6 ) Total score to determine whether response at Week 2 of treatment may predict response at Week 12 in a randomized, double-blind trial of olanzapine versus haloperidol for treatment of patients with first-episode psychosis ( N = 225). Later response was defined as a ≥ 40% and ≥ 50% improvement in PANSS Total0–6 score and as remission. At Week 2, 43% (97/225) of patients were identified as early responders. At a threshold for later response of ≥ 50% improvement in PANSS0–6 Total score, early non-response most strongly predicted later non-response, demonstrating high specificity (74%) and high negative predictive value (80%). As had been seen in the treatment of patients with chronic schizophrenia, early non-response was a robust predictor of subsequent non-response in the treatment of patients with first-episode psychosis.</abstract><cop>Kidlington</cop><pub>Elsevier Ireland Ltd</pub><pmid>21168920</pmid><doi>10.1016/j.psychres.2010.11.017</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0165-1781
ispartof Psychiatry research, 2011-05, Vol.187 (1), p.42-48
issn 0165-1781
1872-7123
language eng
recordid cdi_proquest_miscellaneous_860188813
source Elsevier
subjects Adolescent
Adult
Adult and adolescent clinical studies
Antipsychotic Agents - therapeutic use
Basal Ganglia Diseases - chemically induced
Benzodiazepines - therapeutic use
Biological and medical sciences
Double-Blind Method
Female
Follow-Up Studies
Haloperidol
Haloperidol - therapeutic use
Humans
International Cooperation
Male
Medical sciences
Mental Disorders - drug therapy
Mental Disorders - physiopathology
Neuropharmacology
Olanzapine
Pharmacology. Drug treatments
Prediction models
Predictive Value of Tests
Psychiatric Status Rating Scales
Psychiatry
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Schizophrenia
Time Factors
Treatment Outcome
Weight Gain - drug effects
Young Adult
title Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A14%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20response%20to%20antipsychotic%20therapy%20as%20a%20clinical%20marker%20of%20subsequent%20response%20in%20the%20treatment%20of%20patients%20with%20first-episode%20psychosis&rft.jtitle=Psychiatry%20research&rft.au=Stauffer,%20Virginia%20L&rft.date=2011-05-15&rft.volume=187&rft.issue=1&rft.spage=42&rft.epage=48&rft.pages=42-48&rft.issn=0165-1781&rft.eissn=1872-7123&rft.coden=PSRSDR&rft_id=info:doi/10.1016/j.psychres.2010.11.017&rft_dat=%3Cproquest_cross%3E860188813%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-c96caf86c6a96023661c4a7a342c59396588ef3357a140a2d5f7d6dc626b57703%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=860188813&rft_id=info:pmid/21168920&rfr_iscdi=true